{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:48:57Z","timestamp":1784040537767,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Breast Cancer Clinical Practice Guidelines, organized by the Japanese Breast Cancer Society (JBCS), were published in 2022. We present the English version of the Radiation Therapy (RT) section of the guidelines. The JBCS formed a task force to update the 2018 version of the JBCS Clinical Practice Guidelines. The Background Questions (BQs) contain the standard treatments for breast cancer in clinical practice, whereas the Clinical Questions (CQs) address daily clinical questions that remain controversial. Future Research Questions (FRQs) explore the subjects that are considered important issues, despite there being insufficient data for inclusion as CQs. The task force selected the 12 BQs, 8 CQs, and 6 FRQs for the RT section. For each CQ, systematic literature reviews and meta-analyses were conducted according to the Minds Manual for Guideline Development 2020, version 3.0. The recommendations, strength of recommendation, and strength of evidence for each CQ were determined based on systematic reviews and meta-analyses, and finalized by voting at the recommendation decision meeting.<\/jats:p>","DOI":"10.1007\/s12282-024-01568-4","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T13:01:31Z","timestamp":1712322091000},"page":"347-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition"],"prefix":"10.1007","volume":"31","author":[{"given":"Michio","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Kawamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Ogita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513\u201320.","journal-title":"N Engl J Med"},{"key":"1568_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086\u201394.","journal-title":"Lancet Oncol"},{"key":"1568_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijrobp.2010.04.042","volume":"81","author":"BD Smith","year":"2011","unstructured":"Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American society for radiation oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81:59\u201368.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1568_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","volume":"8","author":"BD Smith","year":"2018","unstructured":"Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: executive summary of an American society for radiation oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8:145\u201352.","journal-title":"Pract Radiat Oncol"},{"key":"1568_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/jjco\/hyab024","volume":"51","author":"M Nozaki","year":"2021","unstructured":"Nozaki M, Kagami Y, Machida R, Nakamura K, Ito Y, Nishimura Y, et al. Final analysis of a multicenter single-arm confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Jpn J Clin Oncol. 2021;51:865\u201372.","journal-title":"Jpn J Clin Oncol"},{"key":"1568_CR6","unstructured":"NCCN. NCCN Clinical practice guidelines in oncology: Breast Cancer, version 8. 2021."},{"key":"1568_CR7","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ijrobp.2014.07.026","volume":"90","author":"N Lalani","year":"2014","unstructured":"Lalani N, Paszat L, Sutradhar R, Thiruchelvam D, Nofech-Mozes S, Hanna W, et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2014;90:1017\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1568_CR8","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1200\/JCO.20.01363","volume":"38","author":"BV Offersen","year":"2020","unstructured":"Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38:3615\u201325.","journal-title":"J Clin Oncol"},{"key":"1568_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","volume":"16","author":"H Bartelink","year":"2015","unstructured":"Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47\u201356.","journal-title":"Lancet Oncol"},{"key":"1568_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13014-019-1327-8","volume":"14","author":"Y Ono","year":"2019","unstructured":"Ono Y, Yoshimura M, Hirata K, Yamauchi C, Toi M, Suzuki E, et al. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation. Radiat Oncol. 2019;14:121.","journal-title":"Radiat Oncol"},{"key":"1568_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ijrobp.2013.02.031","volume":"86","author":"E Rakovitch","year":"2013","unstructured":"Rakovitch E, Narod SA, Nofech-Moses S, Hanna W, Thiruchelvam D, Saskin R, et al. Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis. Int J Radiat Oncol Biol Phys. 2013;86:491\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1568_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaoncol.2016.6948","volume":"3","author":"MS Moran","year":"2017","unstructured":"Moran MS, Zhao Y, Ma S, Kirova Y, Fourquet A, Chen P, et al. Association of radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol. 2017;3:1060\u20138.","journal-title":"JAMA Oncol"},{"key":"1568_CR13","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0140-6736(19)32514-0","volume":"394","author":"FA Vicini","year":"2019","unstructured":"Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394:2155\u201364.","journal-title":"Lancet"},{"key":"1568_CR14","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/S0140-6736(19)32515-2","volume":"394","author":"TJ Whelan","year":"2019","unstructured":"Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394:2165\u201372.","journal-title":"Lancet"},{"key":"1568_CR15","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1200\/JCO.20.00650","volume":"38","author":"I Meattini","year":"2020","unstructured":"Meattini I, Marrazzo L, Saieva C, Desideri I, Scotti V, Simontacchi G, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol. 2020;38:4175\u201383.","journal-title":"J Clin Oncol"},{"key":"1568_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(21)00080-2","volume":"22","author":"R Orecchia","year":"2021","unstructured":"Orecchia R, Veronesi U, Maisonneuve P, Galimberti VE, Lazzari R, Veronesi P, et al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021;22:597\u2013608.","journal-title":"Lancet Oncol"},{"key":"1568_CR17","first-page":"CD007077","volume":"8","author":"BE Hickey","year":"2021","unstructured":"Hickey BE, Lehman M. Partial breast irradiation versus whole breast radiotherapy for early breast cancer. Cochrane Database Syst Rev. 2021;8:CD007077.","journal-title":"Cochrane Database Syst Rev"},{"key":"1568_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307\u201316.","journal-title":"N Engl J Med"},{"key":"1568_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1415369","volume":"373","author":"PM Poortmans","year":"2015","unstructured":"Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317\u201327.","journal-title":"N Engl J Med"},{"key":"1568_CR20","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","volume":"21","author":"PM Poortmans","year":"2020","unstructured":"Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21:1602\u201310.","journal-title":"Lancet Oncol"},{"key":"1568_CR21","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"MGP Ebctcg","year":"2014","unstructured":"Ebctcg MGP, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127\u201335.","journal-title":"Lancet"},{"key":"1568_CR22","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","volume":"35","author":"C Taylor","year":"2017","unstructured":"Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35:1641\u20139.","journal-title":"J Clin Oncol"},{"key":"1568_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2014.10.004","volume":"114","author":"T Grantzau","year":"2015","unstructured":"Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol. 2015;114:56\u201365.","journal-title":"Radiother Oncol"},{"key":"1568_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ijrobp.2013.11.232","volume":"88","author":"LE Warren","year":"2014","unstructured":"Warren LE, Miller CL, Horick N, Skolny MN, Jammallo LS, Sadek BT, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88:565\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1568_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3109\/02841860903352959","volume":"49","author":"O Matzinger","year":"2010","unstructured":"Matzinger O, Heimsoth I, Poortmans P, Collette L, Struikmans H, Van Den Bogaert W, et al. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922\/10925). Acta Oncol. 2010;49:24\u201334.","journal-title":"Acta Oncol"},{"key":"1568_CR26","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/jnci\/djab113","volume":"113","author":"PM Poortmans","year":"2021","unstructured":"Poortmans PM, Struikmans H, De Brouwer P, Weltens C, Fortpied C, Kirkove C, et al. Side effects 15 years after lymph node irradiation in breast cancer: randomized EORTC trial 22922\/10925. J Natl Cancer Inst. 2021;113:1360\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1568_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1245\/s10434-016-5558-8","volume":"24","author":"A Recht","year":"2017","unstructured":"Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, et al. Postmastectomy radiotherapy: an american society of clinical oncology, American Society for radiation oncology, and society of surgical oncology focused guideline update. Ann Surg Oncol. 2017;24:38\u201351.","journal-title":"Ann Surg Oncol"},{"key":"1568_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJM199710023371401","volume":"337","author":"M Overgaard","year":"1997","unstructured":"Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast cancer cooperative group 82b trial. N Engl J Med. 1997;337:949\u201355.","journal-title":"N Engl J Med"},{"key":"1568_CR29","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(98)09201-0","volume":"353","author":"M Overgaard","year":"1999","unstructured":"Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast cancer cooperative group DBCG 82c randomised trial. Lancet. 1999;353:1641\u20138.","journal-title":"Lancet"},{"key":"1568_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1056\/NEJM199710023371402","volume":"337","author":"J Ragaz","year":"1997","unstructured":"Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956\u201362.","journal-title":"N Engl J Med"},{"key":"1568_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jnci\/djh297","volume":"97","author":"J Ragaz","year":"2005","unstructured":"Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116\u201326.","journal-title":"J Natl Cancer Inst"},{"key":"1568_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ijrobp.2013.03.021","volume":"86","author":"C Hennequin","year":"2013","unstructured":"Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86:860\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1568_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamaoncol.2021.6036","volume":"8","author":"YB Kim","year":"2022","unstructured":"Kim YB, Byun HK, Kim DY, Ahn SJ, Lee HS, Park W, et al. Effect of elective internal mammary node irradiation on disease-free survival in women with node-positive breast cancer: a randomized phase 3 clinical trial. JAMA Oncol. 2022;8:96\u2013105.","journal-title":"JAMA Oncol"},{"key":"1568_CR34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2015.63.6456","volume":"34","author":"LB Thorsen","year":"2016","unstructured":"Thorsen LB, Offersen BV, Dano H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34:314\u201320.","journal-title":"J Clin Oncol"},{"key":"1568_CR35","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1200\/JCO.2008.17.4862","volume":"26","author":"RC Chen","year":"2008","unstructured":"Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management \u2013 a systematic review. J Clin Oncol. 2008;26:4981\u20139.","journal-title":"J Clin Oncol"},{"key":"1568_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2019.06.037","volume":"141","author":"R Chow","year":"2019","unstructured":"Chow R, Hoskin P, Schild SE, Raman S, Im J, Zhang D, et al. Single vs multiple fraction palliative radiation therapy for bone metastases: cumulative meta-analysis. Radiother Oncol. 2019;141:56\u201361.","journal-title":"Radiother Oncol"},{"key":"1568_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","volume":"126","author":"SE Rich","year":"2018","unstructured":"Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126:547\u201357.","journal-title":"Radiother Oncol"},{"key":"1568_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.critrevonc.2018.01.006","volume":"123","author":"Y Pin","year":"2018","unstructured":"Pin Y, Paix A, Le Fevre C, Antoni D, Blondet C, Noel G. A systematic review of palliative bone radiotherapy based on pain relief and retreatment rates. Crit Rev Oncol Hematol. 2018;123:132\u20137.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1568_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0936-6555(03)00113-4","volume":"15","author":"WM Sze","year":"2003","unstructured":"Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy\u2013a systematic review of randomised trials. Clin Oncol (R Coll Radiol). 2003;15:345\u201352.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1568_CR40","unstructured":"WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization; 2018. (https:\/\/iris.who.int\/bitstream\/handle\/10665\/279700\/9789241550390-eng.pdf?sequence=1, Accessed 11 Nov 2023)."},{"key":"1568_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7:4\u201312.","journal-title":"Pract Radiat Oncol"},{"key":"1568_CR42","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","volume":"295","author":"H Aoyama","year":"2006","unstructured":"Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483\u201391.","journal-title":"JAMA"},{"key":"1568_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401\u20139.","journal-title":"JAMA"},{"key":"1568_CR44","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037\u201344.","journal-title":"Lancet Oncol"},{"key":"1568_CR45","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.prro.2011.12.004","volume":"2","author":"MN Tsao","year":"2012","unstructured":"Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American society for radiation oncology evidence-based guideline. Pract Radiat Oncol. 2012;2:210\u201325.","journal-title":"Pract Radiat Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01568-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-024-01568-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01568-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T14:32:02Z","timestamp":1714055522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-024-01568-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1007\/s12282-024-01568-4","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MY, CY, NS, YH, KH, JK, MK, and MO have no conflict of interest. YY received research funding from Chugai, Kyowa-Kirin, Eisai, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Takeda, Eli Lilly, Pfizer, and Novartis, received honoraria from AstraZeneca, Chugai, Kyowa-Kirin, Novartis, Eli Lilly, Pfizer, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Eisai, Takeda, MSD, Sysmex, and Exact Science, participated on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Chugai, Novartis, MSD, Eli Lilly, Pfizer, and Daiichi-Sankyo, and is a member of the Board of Director of Japanese Breast Cancer Society and Japan Breast Cancer Research Group. HI received grants from Chugai, Daiichi Sankyo, and AstraZeneca, consulting fees from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, and Giliead, and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. SS received research funding from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, and Daiichi Sankyo, received honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nippon Kayaku, participated on a Data Safety Monitoring Board or Advisory Board of Chugai\/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD, is an executive member of JBCRG, JBCS, JSMO, and BIG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}